Sphingolipids, Lipotoxic Cardiomyopathy, and Cardiac Failure

Heart Failure Clinics

Volumn 8, Issue 4, 2012, Pages 633-641

  Park, Tae Sik ^a   Goldberg, Ira J ^b  

^a Gachon University College of Medicine   (South Korea)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cardiomyopathy; Ceramide; Diabetes; Ischemia; Sphingosine 1 phosphate

Indexed keywords

CERAMIDE; FATTY ACID; G PROTEIN COUPLED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE;

APOPTOSIS; CARDIOMYOPATHY; DIABETES MELLITUS; DISEASE MODEL; ENERGY METABOLISM; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REPERFUSION INJURY; REVIEW;

APOPTOSIS; CERAMIDES; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; HEART FAILURE; HUMANS; LIPID METABOLISM; LYSOPHOSPHOLIPIDS; MYOCYTES, CARDIAC; SPHINGOLIPIDS; SPHINGOSINE;

EID: 84866598990     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.06.003     Document Type: Review

References (71)

1. Borradaile N.M., Schaffer J.E. Lipotoxicity in the heart. Curr Hypertens Rep 2005, 7:412-417.
2. Harmancey R., Wilson C.R., Taegtmeyer H. Adaptation and maladaptation of the heart in obesity. Hypertension 2008, 52:181-187.
3. Summers S.A. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006, 45:42-72.
4. Perman J.C., Bostrom P., Lindbom M., et al. The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction. J Clin Invest 2011, 121:2625-2640.
5. Holland W.L., Miller R.A., Wang Z.V., et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011, 17:55-63.
6. Park T.S., Hu Y., Noh H.L., et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. Journal of lipid research 2008, 49:2101-2112.
7. Holland W.L., Brozinick J.T., Wang L.P., et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007, 5:167-179.
8. Guenther G.G., Edinger A.L. A new take on ceramide: starving cells by cutting off the nutrient supply. Cell Cycle 2009, 8:1122-1126.
9. Yang J., Yu Y., Sun S., et al. Ceramide and other sphingolipids in cellular responses. Cell Biochem Biophys 2004, 40:323-350.
10. Augustus A.S., Buchanan J., Park T.S., et al. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 2006, 281:8716-8723.
11. Hajri T., Ibrahimi A., Coburn C.T., et al. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem 2001, 276:23661-23666.
12. Stowe K.A., Burgess S.C., Merritt M., et al. Storage and oxidation of long-chain fatty acids in the C57/BL6 mouse heart as measured by NMR spectroscopy. FEBS Lett 2006, 580:4282-4287.
13. Opie L.H. Cardiac metabolism-emergence, decline, and resurgence. Part II. Cardiovasc Res 1992, 26:817-830.
14. Opie L.H. Cardiac metabolism-emergence, decline, and resurgence. Part I. Cardiovasc Res 1992, 26:721-733.
15. Randle P.J., Garland P.B., Hales C.N., et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
16. Rodrigues B., Cam M.C., Jian K., et al. Differential effects of streptozotocin-induced diabetes on cardiac lipoprotein lipase activity. Diabetes 1997, 46:1346-1353.
17. Pulinilkunnil T., Rodrigues B. Cardiac lipoprotein lipase: metabolic basis for diabetic heart disease. Cardiovasc Res 2006, 69:329-340.
18. Buchanan J., Mazumder P.K., Hu P., et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005, 146:5341-5349.
19. Ko H.J., Zhang Z., Jung D.Y., et al. Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes 2009, 58:2536-2546.
20. Gil-Ortega I., Carlos Kaski J. Diabetic miocardiopathy. Med Clin (Barc) 2006, 127:584-594.
21. Park S.Y., Cho Y.R., Finck B.N., et al. Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes 2005, 54:2514-2524.
22. Lewis G.F., Carpentier A., Adeli K., et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002, 23:201-229.
23. Boden G., Lebed B., Schatz M., et al. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001, 50:1612-1617.
24. Kankaanpaa M., Lehto H.R., Parkka J.P., et al. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 2006, 91:4689-4695.
25. Jaswal J.S., Keung W., Wang W., et al. Targeting fatty acid and carbohydrate oxidation-a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 2011, 1813:1333-1350.
26. Okere I.C., Young M.E., McElfresh T.A., et al. Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in hypertension. Hypertension 2006, 48:1116-1123.
27. Son N.H., Yu S., Tuinei J., et al. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J Clin Invest 2010, 120:3443-3454.
28. Liu L., Shi X., Bharadwaj K.G., et al. DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J Biol Chem 2009, 284:36312-36323.
29. Haemmerle G., Moustafa T., Woelkart G., et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat Med 2011, 17:1076-1085.
30. Young M.E., McNulty P., Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation 2002, 105:1861-1870.
31. Park T.S., Yamashita H., Blaner W.S., et al. Lipids in the heart: a source of fuel and a source of toxins. Curr Opin Lipidol 2007, 18:277-282.
32. Chiu H.C., Kovacs A., Ford D.A., et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001, 107:813-822.
33. Chiu H.C., Kovacs A., Blanton R.M., et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 2005, 96:225-233.
34. Yagyu H., Chen G., Yokoyama M., et al. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 2003, 111:419-426.
35. Dyntar D., Eppenberger-Eberhardt M., Maedler K., et al. Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 2001, 50:2105-2113.
36. Zhou Y.T., Grayburn P., Karim A., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000, 97:1784-1789.
37. Drosatos K., Bharadwaj K.G., Lymperopoulos A., et al. Cardiomyocyte lipids impair beta-adrenergic receptor function via PKC activation. Am J Physiol Endocrinol Metab 2011, 300:E489-E499.
38. Son N.H., Park T.S., Yamashita H., et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 2007, 117:2791-2801.
39. Basu R., Oudit G.Y., Wang X., et al. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol 2009, 297:H2096-H2108.
40. Yokoyama M., Yagyu H., Hu Y., et al. Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J Biol Chem 2004, 279:4204-4211.
41. Foo R.S., Mani K., Kitsis R.N. Death begets failure in the heart. J Clin Invest 2005, 115:565-571.
42. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation 2007, 115:3213-3223.
43. Pettus B.J., Chalfant C.E., Hannun Y.A. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 2002, 1585:114-125.
44. Torre-Villalvazo I., Gonzalez F., Aguilar-Salinas C.A., et al. Dietary soy protein reduces cardiac lipid accumulation and the ceramide concentration in high-fat diet-fed rats and ob/ob mice. J Nutr 2009, 139:2237-2243.
45. Yang Q., Li Y. Roles of PPARs on regulating myocardial energy and lipid homeostasis. J Mol Med (Berl) 2007, 85:697-706.
46. Finck B.N., Lehman J.J., Leone T.C., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002, 109:121-130.
47. Finck B.N., Han X., Courtois M., et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 2003, 100:1226-1231.
48. Baranowski M., Blachnio A., Zabielski P., et al. PPARalpha agonist induces the accumulation of ceramide in the heart of rats fed high-fat diet. J Physiol Pharmacol 2007, 58:57-72.
49. Burkart E.M., Sambandam N., Han X., et al. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 2007, 117:3930-3939.
50. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
51. Bahr M., Spelleken M., Bock M., et al. Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes. Diabetologia 1996, 39:766-774.
52. Sidell R.J., Cole M.A., Draper N.J., et al. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 2002, 51:1110-1117.
53. Carley A.N., Semeniuk L.M., Shimoni Y., et al. Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function. Am J Physiol Endocrinol Metab 2004, 286:E449-E455.
54. Liu L.S., Tanaka H., Ishii S., et al. The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes. Endocrinology 1998, 139:4531-4539.
55. Vikramadithyan R.K., Hirata K., Yagyu H., et al. Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy. J Pharmacol Exp Ther 2005, 313:586-593.
56. Baranowski M., Blachnio A., Zabielski P., et al. Pioglitazone induces de novo ceramide synthesis in the rat heart. Prostaglandins Other Lipid Mediat 2007, 83:99-111.
57. Shimabukuro M., Higa M., Zhou Y.T., et al. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem 1998, 273:32487-32490.
58. Blazquez C., Geelen M.J., Velasco G., et al. The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Lett 2001, 489:149-153.
59. Holland W.L., Bikman B.T., Wang L.P., et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest 2011, 121:1858-1870.
60. Karliner J.S. Sphingosine kinase and sphingosine 1-phosphate in cardioprotection. J Cardiovasc Pharmacol 2009, 53:189-197.
61. Karliner J.S., Honbo N., Summers K., et al. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2001, 33:1713-1717.
62. Jin Z.Q., Zhou H.Z., Zhu P., et al. Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol 2002, 282:H1970-H1977.
63. Tao R., Zhang J., Vessey D.A., et al. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res 2007, 74:56-63.
64. Vessey D.A., Kelley M., Li L., et al. Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit 2006, 12:BR318-BR324.
65. Duan H.F., Wang H., Yi J., et al. Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Hum Gene Ther 2007, 18:1119-1128.
66. Kennedy S., Kane K.A., Pyne N.J., et al. Targeting sphingosine-1-phosphate signalling for cardioprotection. Curr Opin Pharmacol 2009, 9:194-201.
67. Zhang J., Honbo N., Goetzl E.J., et al. Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol 2007, 293:H3150-H3158.
68. Means C.K., Xiao C.Y., Li Z., et al. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007, 292:H2944-H2951.
69. Theilmeier G., Schmidt C., Herrmann J., et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006, 114:1403-1409.
70. Means C.K., Brown J.H. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res 2009, 82:193-200.
71. Baranowski M., Blachnio-Zabielska A., Hirnle T., et al. Myocardium of type 2 diabetic and obese patients is characterized by alterations in sphingolipid metabolic enzymes but not by accumulation of ceramide. J Lipid Res 2010, 51:74-80.